<DOC>
	<DOCNO>NCT01890746</DOCNO>
	<brief_summary>The purpose randomize , blind , placebo-controlled study provide clinical safety exploratory efficacy data use Eltrombopag adult subject Acute Myeloid Leukemia ( AML ) receive standard induction chemotherapy daunorubicin plus cytarabine . These safety data consider necessary development Eltrombopag adult paediatric patient suffer malignant disease secondary thrombocytopenia . A minimum 120 evaluable subject newly diagnose AML stratify antecedent malignant hematologic disorder age .</brief_summary>
	<brief_title>A Safety Efficacy Study Eltrombopag Subjects With AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Inclusion Criteria Age &gt; =18 year Diagnosed AML accord WHO 2008 classification . Note : subject secondary AML follow Myelodysplastic syndrome secondary previous leukemogenic therapy allow provide record previous MDS history leukemogenic therapy history available . Eligible induction daunorubicin + cytarabine . Eligible give inform consent participate study . Have adequate baseline organ function define follow criterion : Total bilirubin &lt; =1.5 x upper limit normal ( ULN ) except Gilbert 's syndrome , condition indicative inadequate liver function ( i.e . elevation indirect bilirubin ( haemolytic ) absence alanine aminotransferase [ ALT ] abnormality ) . ALT &lt; =3 x ULN . Serum Creatinine &lt; =2.5 x ULN . Adequate cardiac function LVEF &gt; =50 % assessed echocardiogram ( ECHO ) Multi Gated Acquisition Scan ( MUGA . Subjects QT interval correct heart rate accord Bazett 's formula ( QTcB ) &lt; 450millisecond ( msec ) &lt; 480msec subject bundle branch block . The QTc base single average QTc value triplicate electrocardiogram ( ECGs ) obtain brief recording period . Women must either nonchildbearing potential woman childbearing potential men reproductive potential must willing practice acceptable method birth control study . Men female partner childbearing potential must either prior vasectomy agree use effective contraception time randomization 30 day last dose investigational product . Women childbearing potential must negative serum pregnancy test within 7 day first dose study treatment agree use effective contraception study 30 day follow last dose investigational product . Exclusion Criteria A diagnosis acute promyelocytic ( M3 ) acute megakaryocytic leukaemia ( M7 ) . Previous history exposure anthracycline compound . Previous AML treatment ( hydroxyurea ) . Any serious medical condition , laboratory abnormality , psychiatric illness , view treat physician , would place participant unacceptable risk participate study would prevent person give informed consent . History thromboembolic event condition require ongoing use anticoagulation either warfarin low molecularweight heparin . Note : Occlusion central line exclusion . Treatment investigational drug within 30 day 5 half life , whichever longer , precede first dose study medication . Current continue use study treatment period know Breast cancer resistance protein ( BCRP ) inhibitor know Pgp inhibitor . Known active hepatitis B , hepatitis C Human Immunodeficiency Virus ( HIV ) infection . Known hypersensitivity study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>de novo AML</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>leukemia</keyword>
	<keyword>sAML/MDS</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid</keyword>
	<keyword>thrombocytopenia</keyword>
</DOC>